<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="80908" id="root" date="1996-09-27" xml:lang="en">
<title>USA: Lilly gets European approval for Zyprexa.</title>
<headline>Lilly gets European approval for Zyprexa.</headline>
<dateline>INDIANAPOLIS 1996-09-27</dateline>
<text>
<p>Eli Lilly &amp; Co said it received approval through the European Medicine Evaluation Agency in Europe to market Zyprexa in 15 European Union member countries for the treatment of schizophrenia.</p>
<p>Zyprexa is under review by the U.S. Food and Drug Administration and has not been approved for marketing anywhere outside Europe, Lilly said.</p>
<p>Shares in Lilly were up 3/4 to 64-3/4.  </p>
<p>Lilly recently received an approvable letter from the FDA for Zyprexa, indicating the drug could soon get U.S. marketing clearance.</p>
<p>Europe's Committee for Proprietary Medicinal Products cleared Zyprexa for European marketing after evaluating the results of Lilly's data from more than 3,100 individuals in 22 countries, with more than 200 clinical investigators conducting the studies, the company said.</p>
<p>Zyprexa, known chemically as olanzapine, is expected by analysts to be the first of a wave of new anti-schizophrenia drugs to hit the market in the next 12 months.  </p>
<p>In the pipeline are Serlect from Abbott Laboratories Inc, Seroquel from Zeneca Group Plc and Ziprasidone from Pfizer Inc.</p>
<p>These new &quot;atypical antipsychotics&quot; will compete against established drugs for treating the disease, including Risperdal from Johnson &amp; Johnson, Clozaril from Sandoz AG and generically available haloperidol.</p>
<p>Estimates of the size of the U.S. schizophrenia market range from $1 billion to as high as $4.5 billion.  The market is difficult to gauge because only about half of the estimated 2.5 million Americans who suffer from the disease are treated.  </p>
<p>With that in mind, analysts project annual sales for Zyprexa of $1 billion after about five years on the market.</p>
<p>Challenges to the drug and the others that will likely follow it onto the market include cost and the institutional nature of schizophrenia treatment, analysts said.</p>
<p>About two-thirds of schizophrenia patients today receive haloperidol at a cost of about $0.65 per day. The daily treatment costs of the new drugs will be much higher.</p>
<p>The chief advantages of the new drugs, including Zyprexa, are that they cause fewer side-effects than older therapies.</p>
<p>--Chicago Newsdesk 312-408-8787</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="EEC">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
</codes>
<codes class="bip:industries:1.0">
  <code code="I25700">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="C22">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="G15">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="G152">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-09-27"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-09-27"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-09-27"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="INDIANAPOLIS"/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
